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Abstract: Since its discovery and characterization in the early 1980s as a virus that attacks 
the immune system, there has been some success for the treatment of human immunodefi-
ciency virus-1 (HIV-1) infection. However, due to the overwhelming public health impact of 
this virus, a vaccine is needed urgently. Despite the tireless efforts of scientist and clinicians, 
there is still no safe and effective vaccine that provides sterilizing immunity. A vaccine that 
provides sterilizing immunity against HIV infection remains elusive in part due to the following 
reasons: 1) degree of diversity of the virus, 2) ability of the virus to evade the hosts’ immunity, 
and 3) lack of appropriate animal models in which to test vaccine candidates. There have been 
several attempts to stimulate the immune system to provide protection against HIV-infection. 
Here, we will discuss attempts that have been made to induce sterilizing immunity, including 
traditional vaccination attempts, induction of broadly neutralizing antibody production, DNA 
vaccines, and use of viral vectors. Some of these attempts show promise pending continued 
research efforts.
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Introduction
Since its discovery and characterization in the early 1980s as a virus that attacks the 
immune system, leaving patients unable to fight off opportunistic infections, there has 
been an ebb and flow of effective treatments and hope as scientists continue to search 
for ways to eradicate human immunodeficiency virus-1 (HIV-1) from the human popu-
lation similar to what has been accomplished in the case of smallpox. The majority of 
the effort and nearly all of the success has come in the area of patient treatment rather 
than inhibition of contraction or spread of the virus. A class of treatments, antiret-
roviral therapies (ARTs) and later highly active antiretroviral therapies (HAARTs), 
has been the mainstay of disease control during the last 15 years. Notwithstanding 
the increased life span of patients, increased time to full-blown AIDS, and decreased 
contraction of opportunistic infections and AIDS-related diseases (ie, non-Hodgkin’s 
lymphoma, Kaposi’s sarcoma, etc) by patients treated with HAART, there are several 
reasons why development of an HIV-1 vaccine is still warranted. Five of these reasons 
are as follows: 1) nearly two-thirds of the patients who contract HIV-1 live in under-
developed countries and cannot afford the expensive HAART regimen,1 2) both the 
ART and HAART regimen are complex and are disruptive to patients’ lives and diets, 
making long-term compliance an issue,2 3) the potential side effects of ART/HAART 
treatments negatively affect the long-term health of patients and include diabetes, 





and 5) the   presence of latent HIV-1 reservoirs harboring viral 
strains that were produced through mutation throughout the 
duration of the infection of the host also play a role in the 
failure of HAART.6 These reasons, as well as many others, 
underscore the need for a prophylactic HIV-1 vaccine.
Possibly, the strongest argument for development of 
a prophylactic vaccine may be the need for control of the 
virus spread worldwide. Every day, 7500 patients world-
wide are infected with HIV-1.1 Production of a vaccine that 
could inhibit infection, reduce spread, or both would aid 
in the reduction of the burden of AIDS and AIDS-related 
diseases. The expenses incurred by the AIDS epidemic can 
hardly be calculated. They range from tens of thousands of 
dollars per patient for the HAART regimen, to millions of 
dollars required for building of orphanages by governments 
for children whose parents have succumbed to the disease, 
to the unknown cost of educational materials and condoms 
in the effort to prevent further spread of the disease. This 
public health challenge has not gone unnoticed and has been 
addressed by scientists’ ongoing efforts to develop a safe and 
effective HIV-1 vaccine.
Prophylactic vs therapeutic vaccines
A prophylactic HIV-1 vaccine would offer sterilizing immu-
nity to patients, preventing infection upon presentation of the 
virus. A prophylactic vaccine must also be effective at all pos-
sible portals of HIV-1 entry, especially the mucosa.7 For this 
to occur, the vaccine must offer broad and durable immunity. 
Several consortia have worked diligently to produce a vac-
cine that will induce broadly reactive neutralizing antibodies 
(Nabs). These consortia include major international efforts as 
well as efforts of individual countries, regions, and institu-
tions including, but not limited to: the International AIDS 
Vaccine Initiative Neutralizing Antibody Consortium,8 the 
Center for HIV-AIDS Vaccine Immunology, the HIV Vac-
cine Trials Network, US Military HIV Research Program, 
the Collaboration for AIDS Vaccine Discovery, and the 
Vaccine Research Center at the National Institutes of Allergy 
and Infectious Diseases of the National Institutes of Health. 
To date, however, no HIV-1 candidate vaccine has induced 
broadly reactive Nabs.8
In the absence of a vaccine that can prevent infection 
of HIV-1, there are still many benefits to be realized from 
production of a therapeutic vaccine. A therapeutic vaccine 
would be supremely valuable if it were able to increase the 
titer of virus necessary for infection, increase the time to 
clinical manifestation of virus, control viral load after infec-
tion, and reduce secondary transmission.9–13 A vaccine that 
could induce this type of response would invariably decrease 
contagiousness, decrease the need for costly and potentially 
dangerous ART/HAART, and decrease the number of oppor-
tunistic infections of patients.
While the effect of controlling the normal HIV-1 pathol-
ogy with therapeutic vaccines will be favorable for the 
individual patient as well as society, the effect of preventing 
HIV-1 infections in humans with a prophylactic vaccine is 
also broadly appealing. This potential for eradicating the 
HIV-1 virus from human hosts drives scientists to continue 
to find ways to circumvent the challenges presented by this 
unique virus in order to induce production of the Nabs that 
are critical for sterilizing immunity. This review, therefore, 
will focus on the specific challenges presented by HIV-1 and 
strides that have been made toward creating a prophylactic 
vaccine, including past efforts that have failed and lessons 
that have been learned from those failures. We will also 
discuss novel vaccine options and some of the promising 
trials that are currently underway.
Current challenges to creating  
an HIV-1 vaccine
While several problems face scientists who are attempting to 
create an HIV-1 vaccine, three problems in particular have 
posed extremely daunting challenges. These three problems 
are 1) degree of diversity of the virus, 2) ability of the virus to 
evade the hosts’ immunity, and 3) lack of appropriate animal 
models in which to test vaccine candidates. These three major 
problems will be discussed in more detail below.
Degree of diversity
Traditionally, prophylactic vaccines have been made by expos-
ing some part of a pathogen’s structure as an antigen to the 
host’s immune system, and eliciting an immune response, 
resulting in the production of long-term memory lymphocytes 
that are capable of mounting a strong immune response upon 
later infection with the pathogen. The premise upon which 
this manipulation of the immune system is based is the abil-
ity of the immune system to make long-lasting antibodies to 
conserved structures on exposed proteins that are native to the 
pathogen. Ideally, both humoral and cell-mediated immunity 
would be induced creating long-lasting immunity. Traditional 
attempts to recreate this process using live attenuated simian 
immunodeficiency virus-1 (SIV-1) viruses in an effort to 
vaccinate macaques against SIV-1 have been proven safe and 
effective in macaques that were subsequently challenged with 
SIV-1.14,15 However, an incidental study of the effect of live-
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the long terminal repeat) was proven pathogenic in humans 
when three out of six treated patients developed late-onset 
immunosuppression.16–18 Killed viruses have also been tested 
as a potential vaccine approach, but safety concerns have 
halted their use. These safety concerns include incomplete 
inactivation of the virus leading to potential residual infectiv-
ity during the vaccine preparation.19 Due to the ineffective-
ness of traditional vaccine approaches to date, scientists have 
attempted to use recombinant HIV-1 proteins to stimulate the 
production of Nabs. These attempts failed due to their inability 
to induce a lasting, broad range of Nabs that would inhibit 
infection in humans.20–23 Perhaps these failures are a result of 
the inherent diversity of HIV-1. This diversity has presented 
a major roadblock to development of a prophylactic vaccine. 
There are three main groups of HIV-1 (M, O, and N)24 as well 
as a recently discovered group, P.25 Each group consists of 
several subtypes, clades. The various clades display biological 
differences with respect to transmission,26 replication,27 and 
disease progression.28,29 These differences result in an inabil-
ity to produce a generalizable vaccine that would induce the 
breadth of Nabs necessary to counter an infection by a wide 
range of HIV-1 clades that may be encountered in a natural 
setting.30 The degree of diversity seen in HIV-1 is greater than 
that of any other virus observed.31,32 This problem is being 
addressed by development of multiclade (multiple env and/
or subtype B gag, pol, nef)33,34 and mosaic vaccines which 
incorporate sets of 10 immunogenic proteins from 4 different 
clades or bivalent proteins from clades B and C.35–37 There are 
proof of principle studies that illustrate immunological protec-
tion against HIV-1 in nonhuman primates that were passively 
treated with broadly reactive Nabs.38–40 These studies show that 
protection against infection with HIV-1 can be conferred by 
the presence of broadly reactive Nabs. The next step toward 
production of a prophylactic vaccine would involve induction 
of production of these or similar broadly reactive Nabs by the 
host’s immune system.
immune evasion
The rate at which the HIV-1 virus mutates, due to the nature 
of the reverse transcriptase enzyme responsible for transcrib-
ing its RNA, ensures that nearly every daughter virion will 
have a different genome than its parent.41 When these changes 
occur in the HIV-1 Env protein that is needed for antibody 
recognition, they inhibit the immune system’s ability to 
mount a sufficient response. One attempt to circumvent this 
problem has been to induce the production of Nabs to the 
conserved regions of HIV-1 proteins. A major problem with 
this approach is that the conserved regions of HIV-1 proteins 
are often shielded from exposure to Nabs within the HIV-1 
envelope. The native structure of the envelope protein, report-
edly the only HIV-1 protein susceptible to Nabs,31 shields it 
from the immune system as a glycosylated trimer of heterodi-
mers. The glycosylation of the envelope protein allows for 
the carbohydrates to masquerade as ‘self’ thereby forming 
an immunologically silent face and protects neighboring 
epitopes via an ‘evolving glycan shield’.42–44 Additionally, 
the gp41 coreceptor binding site, another conserved site, is 
not presented until primary binding to CD4+ has occurred.45 
An attempt to create antibodies to the CD4-binding region of 
the gp120 protein was made in rhesus macaques in 2007 and 
results indicated that vaccinated hosts were able to withstand 
challenge with SHIV .46 Other attempts to create an HIV-1 
vaccine have focused on overcoming the ability of HIV-1 
to escape immune surveillance through use of antibodies 
that are able to neutralize diverse isolates of HIV-1. These 
antibodies include PG9, PG16,47 2F5, 2G12, 4E10, b12,48–51 
and most recently sCD4-17b52 and others.53 Identification 
of these antibodies gives hope that their induction or the 
induction of other such broadly reactive Nabs may provide 
the basis for a prophylactic vaccine in the future.
Lack of appropriate animal models
The use of animal models for development of therapeutics 
offers the benefit of thorough testing and validation prior to 
introduction of a vaccine in humans. In the past, vaccines were 
made by observing and then mimicking the immune response 
mounted by individuals who had recovered from a particular 
disease. To date, however, there are no known cases of indi-
viduals who have recovered from HIV-1 infection. However, 
data can be gathered from long-term nonprogressors – patients 
who have been infected with HIV-1 for at least 7 years and do 
not display any HIV-1-related symptoms.54,55 Another option 
that may be critical to the development of a prophylactic 
vaccine is the use of relevant animal models. Such models 
will allow for analysis of the effect of a potential vaccine on 
an intact host prior to use in humans.
One particular challenge with the use of animal models 
for development of a prophylactic HIV-1 vaccine is that there 
are very few naturally occurring disease models of HIV-1. 
Only a few nonhuman primates are susceptible to infection 
with HIV-1 and infected animals do not progress to AIDS.56 
Therefore, it is important to use other disease models that 
mimic the HIV-AIDS pathologic progression.57 One such 
potential model is feline immunodeficiency virus (FIV). FIV 
was discovered in 1986 and is known to cause an AIDS-like 





in humans.58 A vaccine for FIV was approved by the FDA 
in 2002.59 While the FIV model is potentially informative, 
its use is not sufficient as a basis for development of a pro-
phylactic HIV-1 vaccine.
An ideal animal model would display a pathological 
response to infection with HIV-1 that is very similar to the one 
that occurs in humans. Unfortunately, HIV-1 does not cause 
pathology leading to the development of AIDS in any host 
other than humans.60–63 However, animal models have been 
developed and used that allow partial understanding of the 
pathology of HIV-1, the natural immunological response to 
infection, and the response of the host to novel therapeutics. 
One of these models involves the simian immunodeficiency 
virusMAC (SIVMAC) that replicates and causes an AIDS-like dis-
ease in baboons, cynomolgus, and pigtailed macaques. While 
the similarities of SIVMAC to HIV-1 have allowed for insight 
into pathology, transmission, and immunological response of 
the infected host to the virus, the differences between SIVMAC 
and HIV-1 are still too great to be able to draw conclusions 
regarding potential human responses to an HIV-1 prophylac-
tic vaccine.63 Therefore, to broaden the scope of animal model 
usage, a chimeric SHIV virus was engineered to incorporate 
both SIV and HIV-1 proteins or genes.64 While macaques 
infected with SHIV do go on to develop AIDS, the time to 
progression is much different from the time to progression 
to AIDS of HIV-1-infected humans. Infection of macaques 
with SIVmac251 strain mimics HIV-1 infection in humans by 
leading to chronic, slow disease progression. Route and dose 
required for infection, viral tropism, replicative capacity of 
the viruses, and pathology of SIV/SHIV-infected monkeys 
are all very different than these parameters in humans.65,66 
This distinction has been well characterized by the recent 
Phase IIb STEP trial, which involved 3000 healthy, unin-
fected volunteers. The result of this trial was termination at 
its first scheduled efficacy assessment due to its failure to 
suppress viral load in subsequently infected individuals and 
then-suspected increased HIV-1 infection due to interac-
tion of the immune system with vaccine components.67 The 
vaccine, a recombinant adenovirus serotype 5 (Ad5) virus 
incorporating the gag, pol, and nef genes from HIV-1, had 
been previously tested in an SHIV model in macaques and the 
results of that experiment were not suggestive of the results 
of the human trial.68
This disparity underscores the need for animal models 
that more closely reflect the pathology seen in human infec-
tion with HIV-1 as well as identification of immunological 
correlates of protection that reflect control of HIV-1 viral load 
in human subjects. Therefore, the search for an appropriate 
animal model or the appropriate use of current animal models 
in the search for a prophylactic HIV-1 vaccine continues. 
Until a model can be derived that will allow for observa-
tion of each stage of infection, progression of disease, and 
response of the immune system in a way that is comparable 
to this process in humans, we will not be able to logically 
predict which vaccine candidates should be moved forward 
to clinical trials.
Several attempts to stimulate the immune system to pro-
vide protection against HIV infection have been attempted 
so far (Table 1). Hope for creating a prophylactic vaccine 
lies in the ability of the scientific community to identify and 
induce a broad neutralizing antibody response that would 
offer sterilizing immunity to vaccinated patients. To this end, 
several novel approaches are being studied.
Novel vaccine options
As mentioned in the previous section, there are several daunt-
ing problems facing scientists who are attempting to create an 
HIV-1 vaccine. In hopes of creating a vaccine which elicits 
sterilizing immunity to HIV-1, researchers have focused 
their efforts on (1) the use of plasmid DNA vaccines, (2) live 
recombinant vectors for vaccine development (expressing or 
presenting HIV antigens), and (3) mucosal immunity. These 
critical topics will be discussed in more detail below.
Plasmid DNA vaccines
Vaccines should elicit a robust immune response that is 
long lasting and is able to provide protection against various 
strains of a pathogen. Plasmid DNA vaccinations can induce a 
strong humoral and T-cell response. DNA-based vaccination 
has been used as a powerful tool to fight against parasitic, 
fungal, bacterial, and viral infections.115–119 There are multiple 
advantages for using plasmid DNA for vaccination: they 
are generally safe, nontoxic, and through the delivery of a 
gene encoding important immunogenic epitopes, the DNA-
based vaccine exploits biosynthetic machinery of the host 
cell. One such example was in 1990, whereby Wolff and 
colleagues illustrated protein expression after intramuscular 
(IM) injection of plasmid DNA into myocytes.120 Despite 
these promising results, there had been speculation regard-
ing DNA vaccination strategies. For example, it was shown 
that protein production in response to DNA plasmids that 
contained HIV inserts elicited substantial cellular response 
in mice and nonhuman primates. However, these products 
were poorly immunogenic in humans.
One strategy to improve immune response of the plas-
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Table 1 Historical vaccine attempts to inhibit Hiv-1 infection
Vaccine attempt Mechanism of action Outcome References
Live attenuated
Nef-deleted viruses Deletion of nef gene in Siv;  
deletion of nef gene in Hiv
excellent short-term protection in  
nonhuman primates. Disease-causing  
mutants generated from vaccine
14,69–72
Siv1A11 Deletion of vpr and a portion of gp41 Animals never developed immunodeficiency 
but were not protected against challenge  
with wild-type virus
73
SivMAC-M4 Multiple mutations in the transmembrane protein 
intracytoplasmic domain
Animals developed immunodeficiency 1 year  
after infection with this virus but showed low 




Simian model Formaldehyde-inactivated or subunit Siv 
vaccines
Animals resistant to infection with Hiv  
produced in human cells but not Hiv  
produced in macaque cells
75–77
Feline model Dual inactivated strains used for vaccination Protection against heterologous  
strains conferred
78–81
Protein subunits and synthetic peptides
Recombinant env  
glycoproteins
Stimulate humoral immune response Some antibody production and lymphocyte  
proliferation but no clinical benefit to date
82–90
Recombinant Gag subunits Stimulate humoral response induced production of anti-p24 antibodies 
but no clinical benefit
91–94
DNA vaccines
Direct injection encoding Hiv-1 env and rev Produced a robust humoral and  
cellular response
95
Viral vectors expressing HIV-1 genes
Retroviral vectors CD4-specific transduction of HIV-1  
genes: env, vpu, tat, and rev
induction of humoral and cellular anti- 
Hiv-1 responses in vivo
96,97
Rabies virus Attenuated Rv-expressing Siv-1 proteins SivMAC-challenged macaques expressed 
higher antibody and CTL responses 
than nonvaccinated controls
98,99
Alphavirus Hiv-1 strain R2 env expression  
followed by administration of  
soluble oligomeric gp120
induction of humoral and cell-mediated 
responses that were protective against 
heterologous Hiv challenges in rhesus 
macaques
100
Canarypox Prime with ALvAC-Hiv (vCP1521)  
boost with AiDSvAX B/e
inhibition of infection noted in vaccinees, 
although viremia was not reduced in those  
vaccinees that did become infected
101
Adeno-associated viruses Gene transfer in muscle of antibodies  
or antibody-like immunoadhesins
Long-lasting neutralizing activity in serum  
of monkeys against Siv
102
Ads vaccination with a recombinant Ad5 construct induction of humoral and cellular responses 




virus cocktails Hiv-1 vaccination with successive immunizations 
containing recombinant DNA, recombinant  
vaccinia virus, and recombinant env proteins
Following challenge with SHiv strains that  
were not used in vaccination cocktail, four of 
six vaccinated macaques lived through the  
44-week observation period as compared  
to one of six control macaques
107
Fibroblasts immunization with retroviral vector-transduced 
fibroblasts expressing human immunodeficiency  
virus type-1 iiiB eNv/Rev proteins
induction of CTL and antibody responses 
in rhesus monkeys
108
Dendritic cell-based vaccines immunization with retroviral-vector transduced 
dendritic cells
induction of CTL and antibody responses  
in cynomolgus monkeys
109
virus-like particles Goal – present artificially produced partial HIV-1 
proteins in order to stimulate Nabs
Humoral and cellular response  
achieved in mice or rabbits
110–114
Note: aProof of principle studies using Siv or Fiv.





  plasmids coding for cytokines (eg, INF-g, IL-2, IL-12, IL-18, 
and IL-15).121–124 A second strategy which has been utilized 
to improve plasmid DNA vaccination has been the admin-
istration of plasmid DNA with adjuvants (eg, CpG oligode-
oxynucleotides), or the use of DNA-delivery systems (eg, 
microparticles, cochleates, and linear polyenimines).125–128 
A third strategy to improve vaccine efficacy involves the 
coadministration of plasmid DNA in combination with viral 
vectors. For instance, research performed by Harari and col-
leagues in 2008 demonstrated that vaccination by means of an 
HIV-1 clade C DNA prime in combination with a pox vector 
(NYVAC) boost induces a reliable polyfunctional and long-
lasting anti-HIV T-cell response in human participants.129 
Along these same lines, work recently published by Jaoko 
and group demonstrated safety and immunogenicity of a 
multiclade HIV-1 Ad-based vaccine alone or in combina-
tion with a multiclade HIV-1 DNA vaccine in Africa. These 
results also demonstrated that DNA priming increased the 
frequency and magnitude of cellular and humoral responses; 
however, there was no effect of recombinant Ad5 dosage on 
immunogenicity endpoints.130
The previously mentioned DNA-delivery strategies have 
been used in combination with viral vectors or alone by 
means of a variety of immunization routes (eg, IM, intrave-
nous [IV], intradermal [ID], intranasal [IN], oral, rectal, or 
vaginal). In the majority of reported studies, DNA vaccines 
have been administered by the IM and/or ID routes. However, 
as it relates to HIV vaccination, mucosal immunity could 
potentially be an important factor to consider, with mucosal 
immunity being achieved optimally by IN or oral routes of 
administration. The topic of mucosal immunity will be dis-
cussed in more detail in a later section within this review.
After immunization, it is assumed that the DNA vaccina-
tion immunogen is produced in the skeletal muscles, dendritic 
cells, and macrophages at the site of immunization. However, 
in adults, the skeletal muscles are not involved in a high level 
of protein synthesis as compared to the liver. Therefore, the 
delivery of DNA to cells, which are capable of high protein 
synthesis, such as hepatocytes, epithelia cells of the intestines, 
or salivary pancreas, may result in high levels of protein 
expression. The hepatocytes express enzymes involved in 
the formation of intrachain and interchain disulfide bonds 
required for proper folding and assembly of proteins. In 
addition, the liver expresses glycosyltranferases, which are 
essential for synthesis of both N- and O-linked glycan side 
chains; this may not be the case for other cell types,131,132 the 
significance of this point being the fact that broadly cross-
clade Nabs such as 2G12 recognize glycan moieties on the 
heavily glycosylated HIV-1 envelope antigens.44,133,134 Another 
advantage of protein expression within the liver is that signifi-
cantly lower amounts of DNA are needed for protein expres-
sion of a particular antigen in the hepatocytes vs another cell 
type. For the immunization of humans, milligram quantities 
of DNA are necessary to achieve adequate levels of immune 
response.119 Any method whereby there would be a reduction 
in DNA quantity needed to vaccinate humans would provide 
significant economic advantages. Based on the previously 
mentioned reasons, it is not a surprise that the liver has been 
exploited extensively as a site for gene delivery due to its 
ability to produce proteins and glycoproteins.135–138
Hydrodynamic delivery is the application of controlled 
hydrodynamic pressure in capillaries to enhance endothelial 
and parenchymal cell permeability; this methodology had its 
inception in the late 1990s with investigations into intravas-
cular injection of plasmid DNA solution for gene delivery in 
whole animals.139–142 Hydrodynamic plasmid DNA delivery 
is well tolerated in mice. In 2008, Raska and colleagues 
demonstrated in mice that IV hydrodynamic vaccination 
with HIV-1 envelope DNA injections resulted in high levels 
of expression of HIV antigen in the liver. In mice, immuno-
logical data illustrated that hydrodynamic administration of 
HIV-1 plasmid DNA was superior to vaccination with DNA 
by IN, ID, IM, and intrasplenic routes. Further results illus-
trated that after boosting, hydrodynamic vaccination yielded 
levels of HIV-1-specific antibodies that were 40-fold higher 
than those elicited by other routes tested.132
However, this delivery scheme is not feasible in large 
animals and humans. As an alternative, receptor-mediated 
DNA binding to hepatocytes could be a viable approach. 
  Molecules with terminal galactose residues covalently linked 
to DNA are recognized by the hepatocyte-expressed galactose-
specific asialoglycoprotein143 receptor for internalization.144 
This alternative would avoid delivery through the hepatic 
system and the need for expansion of the blood volume. 
In addition, galactose-linked DNA packaged in delivery 
vehicles such as liposomes, choleates, or microspheres can 
be given by oral administration, which would be absorbed by 
the intestine and ultimately delivered to the hepatic vein. As 
an additional alternative to hydrodynamic delivery in humans, 
it might be possible to express HIV antigens in the liver by 
means of plasmid DNA delivery via viral vectors such as the 
Ad. Ads have been shown to transduce the liver efficiently 
in vivo by means of the hexon proteins.145,146 In this regard, 
production of translation of HIV-1 proteins primarily in the 
liver might allow for the production of heavily glycosylated 
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Live recombinant vectors for vaccine 
development
Viral vectors are potent inducers of cellular and humoral 
response. Viral vectors can express proteins from bacteria 
or viral pathogens to vaccinate against infectious diseases. 
There are several viral vaccine vectors that have been used 
successfully in models for vaccination. These vectors include 
alphaviruses, human rhinoviruses (HRVs), Ads, picornavi-
ruses, poxviruses, measles viruses, influenza, and vaccinia 
viruses.30,129,147–156 Each of these vectors has its respective 
disadvantages and advantages with respect to vaccine devel-
opment. Some advantages of a few of these vectors include 
their ability to naturally infect a wide variety of cell types and 
tissues of interest.157–162 Each respective vector has its own 
set of disadvantages. For instance, one disadvantage of using 
the poliovirus or the HRV as a vaccine vector is the insert 
size limit restriction of these vectors as compared to the large 
insert size (∼8 kb) accommodation of Ad vectors.
The most common disadvantage of the majority of viral 
vaccine vectors is reduced vaccine efficacy due to vector pre-
existing immunity (PEI).163–167 Various strategies have been 
employed to circumvent the problems associated with vector 
PEI. Specifically, as it relates to Ad vectors, PEI is a tremen-
dous problem. Of the identified serotypes of Ad vectors, 
human serotypes 5 (Ad5) and 2 (Ad2) have been the most 
extensively used for gene therapy protocols. Ad5 has been 
used for HIV-1 vaccination protocols, most recently in the 
STEP study. As it relates to Ad2 and Ad5, PEI to these vectors 
may be found in up to 50% of the American population and 
up to 95% of the population of other countries. This Ad PEI 
can limit the effectiveness of Ad-based vaccinations.168–170 To 
circumvent Ad2 or Ad5 PEI, researchers have employed the 
use of vector chimeras,166,171 use of alternative serotypes,172–178 
and the use of nonhuman Ads,151 such as chimpanzee Ad. The 
chimpanzee Ad virus was demonstrated to not be significantly 
neutralized by human sera, which gives chimpanzee Ad an 
advantage for human vaccine development.179–181
Other strategies have been used to reduce the immune 
response against Ad vectors such as the use of helper- 
dependent Ad (HD-Ads) vectors,182–187 the use of Ad deliv-
ery in combination with biochemical modifications such as 
PEGylation,188–194 and the use of vector delivery by means 
of cell vehicles.195,196 With respect to the HD-Ads, these 
vectors were produced to further increase the safety and 
cloning capacity of first-generation Ad vectors. HD-Ads 
lack Ad genes and contain only the packaging signals and 
end terminal repeats. These vectors were designed to avoid 
cellular immunity and diminish liver toxicity, thus promoting 
long-term transgene expression.197–200 The reduced immune 
response against HD-Ads has allowed for transgene expres-
sion in mice and baboons for years.182,183,185,200 This long-term 
transgene expression could be helpful for antigen production 
for an HIV vaccine, thus producing an opportunity to have 
increased protection against HIV , with reduced frequency 
of vaccinations.
Although Nabs to Ad5 may reduce the immunogenicity 
of Ad5-based vectors in animal model systems, their effect 
on the immunity in subjects with previous Ad5 exposure is 
still largely unknown. As previously mentioned, the STEP 
trial, which tested a Merck recombinant Ad5 (rAd5) vaccine 
(encoding HIV-1 gag, pol, and ne1 genes), failed to yield 
protection, either by lowering viral load or by decreasing 
acquisition of infection.13 Analysis of data from this study 
aroused speculation that subjects with pre-existing Nabs 
from wild-type Ad5 infection had an increased risk of HIV 
infection after vaccination. One recent study has shown that 
there was no causative role for Ad5-specific CD4+ T cells in 
increasing HIV-1 susceptibility in the Merck trial.201 In this 
regard, there are multiple studies ongoing to elucidate a con-
crete finding with respect to the role of Ad5 PEI and increased 
activation of CD4+ T cells in the mucosal milieu.202,203
Recently, there was a report by Cheng and colleagues that 
attempted to characterize the specificity of rAd5 Nabs in Ad5-
immune subjects and determine the impact of Ad exposure 
on immune responses elicited by Ad5-based vaccinations. 
Cheng and colleagues reported that rAd5 Nabs were directed 
toward different components of the Ad virion, depending 
on whether the Ad5 infection was natural or from Ad-based 
HIV vaccine trials. For example, Ad Nabs generated by 
natural infection are directed primarily to fiber components, 
while vector exposure elicits responses primarily to capsid 
proteins other than fiber. Nabs elicited by natural infection 
significantly reduced the CD8+ and CD4+ cell responses to 
HIV Gag after DNA/rAd5 vaccination. This report concluded 
that Ad5 Nabs differ based on the route of exposure and that 
previous Ad5 exposure compromises Ad5 vaccine-induced 
immunity to weak immunogens, such as HIV-1 Gag.204 These 
results have a tremendous impact on HIV-1 vaccine trials and 
the design of next generation viral vaccine vectors.
Viral vectors such as Ad, influenza, and polio have been 
used as vaccine vectors for many reasons. One important 
advantage of these vectors, which makes them attractive, 
is that they can provide mucosal immunity because they 
can easily infect the mucosal surfaces as well as act to 
induce cytokine and chemokine production at the mucosal 





being able to be delivered orally, without the use of needles. 
This is an important fact in developing countries where needle 
cost is prohibitive to vaccine administration. As it relates to 
HIV vaccine development, mucosal immunity is a debatable 
factor to consider.
Mucosal Hiv immunity
When deciding upon a vaccine agent, the importance of con-
sidering if the ultimate goal is to induce systemic immunity, 
mucosal immunity, or both is worth careful consideration.205–207 
It is believed that 80% of HIV-1 i  nfection will occur from 
heterosexual viral transmission and most of the rest will occur 
from homosexual or perinatal transmission.152 Although the 
biology of sexual transmission is poorly understood, it is 
clear that the essential first step in the infection pathway is 
the transfer of infectious virus or HIV-infected cells through 
the mucosal surfaces. After HIV has entered a new host, the 
HIV or HIV-infected cells will soon encounter susceptible 
host target cells at the mucosal point of entry where the virus 
replicates and then invades local lymphatic tissues, initiat-
ing systemic HIV infection. On this basis, strong immunity 
is required to provide a protective immunological barrier 
at the most common point of entry, the mucosal surfaces 
of the reproductive tract. Due to the compartmentalization 
of the secretory and systemic immune systems, parenterally 
administered antigens do not consistently stimulate mucosal 
immunity.152 Therefore, it is important to consider a vaccine 
regime that induces mucosal immunity.
Since CD4+ CCR5+ memory T cells are the primary target 
of HIV infection in the gut and mucosa and rapid depletion 
of this subset occurs early after infection,208,209 several stud-
ies have investigated the role of HIV mucosal immunity. 
Previous studies have demonstrated the importance of a 
mucosal SIV/HIV vaccine producing both strong mucosal 
antibody and CD8+ response capable of blocking the escape 
of virus from the intestinal mucosa into systemic lymphoid 
organs.207,210–214 However, in other instances, the necessity 
of exclusive mucosal HIV immunity will be further debated 
based on the promising results found in a heterologous 
prime/boost regimen using DNA/89.6-expressing SIV and 
HIV-1 transcripts215,216 and modified vaccinia virus Ankara 
(MVA/89.6)-expressing SIV and HIV-1 transcripts under 
the control of vaccinia virus early/late promoter. In this 
case, either ID or IM DNA/MVA vaccination was able to 
provide protection against a intrarectal SHIV-89.6 chal-
lenge.153 Along these same lines, recently, promising results 
were found by Hessell and colleagues in 2010. Hessell and 
colleagues demonstrated that after an IV administration of 
monoclonal antibodies 2F5 or 4E10 to six monkeys followed 
by a SHIVba-L challenge, five out of six monkeys from either 
group showed complete protection and sterilizing immunity. 
A low level of viral replication could not be ruled out for the 
six monkeys in either group.217
Replicative Ad yields a robust immune response at the 
mucosal sites partly because Ad is known to infect and repli-
cate in epithelial cells.218–221 Various strategies have been used 
to achieve mucosal immunity via the oral route. One such 
strategy embodies the development of replication-defective 
recombinant Ad serotype 41 (Ad41) vector.222 Serotype 41 
vectors are being currently used because Ad41 has a natural 
tropism for the gut and causes no pathological disease outside 
of the gastrointestinal tract.223 Ad41 vectors are likely to have 
a preferential tropism for the gut because Ad41 appears to 
have a resistance to acidic pH224 and the capsid configuration 
of long and short fibers allows the Ad41 virus to preferentially 
infect the gut.177,225
Live recombinant vectors for vaccine 
development engineered to  
express/present Hiv-1 antigens
As previously mentioned, viral vectors are potent inducers 
of cellular and humoral responses. Of note, viral vectors 
have been practically used for human applications and have 
progressed treating a variety of disease contexts such as 
cancer and infectious diseases.226–229 Traditional viral vector 
immunization embodies the concept that the vector uses the 
host cell machinery to express antigens, which are encoded 
as transgenes within the viral vector. Cellular and humoral 
immune responses are generated against these antigens. Over 
the last 20 years, several viral vectors have been derived to 
express HIV-1 antigens for vaccine purposes.
Some researchers have taken an alternative approach to 
conventional transgene expression of antigens by means of 
viral vectors; this alternative approach embodies the capsid 
incorporation of antigens. This innovative paradigm is based 
upon the vector presenting the antigen as a component of the 
capsid rather than an encoded transgene. Incorporation of 
immunogenic peptides into the vector capsid offers potential 
advantages. In this regard, the processing of the capsid-
incorporated antigen via the exogenous pathway should 
result in a strong humoral response similar to the response 
provoked by native Ad capsid proteins. In this arrange-
ment, potentially, HIV peptide antigens accrue the potent 
immunostimulatory effects of the native Ad vector capsid 
proteins, which effectively perform an adjuvant function. 
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capsid proteins with repetitive vector administration should 
achieve a booster effect against the incorporated antigen.230 
Most importantly, as it relates to HIV infection, this strategy 
yields the potential of generating antibodies to HIV proteins. 
Recent crystallographic, cryo-electron tomography, and 
molecular modeling studies have provided valuable insight 
to molecular surfaces recognized by antibodies as well as 
assisted in rationale vaccine design of immunogens.231–235 
These structural technologies can also potentially improve 
the abilities of scientists to advance the antigen capsid-
incorporation strategy. If the antigen capsid incorporation 
is effective, it can provide a way forward with respect to 
inducing sterilizing immunity.68,236,237
The antigen capsid-incorporation strategy has been 
used for Ad-based vaccines in the context of many 
diseases.230,238–242 One of the first examples where the antigen 
capsid-  incorporation strategy was used was with research 
performed by Crompton in 1994.242 Crompton and colleagues 
inserted an eight-amino acid sequence of the VP1 capsid pro-
tein of poliovirus type 3 into two regions of the Ad2 serotype 
hexon. One of the chimeric vectors produced grew well in 
tissue culture. In addition, antiserum raised against the Ad 
with the polio insert specifically recognized the VP1 capsid 
of polio type 3. As it relates to Ad5 serotype, Wu and group 
demonstrated that His6 epitopes could be incorporated into 
Ad hexon hypervariable regions (HVRs) 1–7 (now reclassi-
fied as 1–9) without perturbing viral viability and any major 
biological characteristics such as replication, thermostability, 
or native infectivity. This study by Wu and colleagues dem-
onstrated that His6 appeared to be surface exposed at these 
regions.243 With respect to peptide incorporation within Ad5 
hexon, HVR2 and HVR5 appear to be the most promising 
locales for peptide/antigen incorporation based on X-ray and 
peptide analyses along with molecular studies.244 Our labora-
tory and others have focused on incorporations at HVR5 or 
single-site incorporations (such as fiber and pIX).230,238–241-
,243,245,246 However, we recognized that the ability to place 
antigen within multiple sites of the Ad capsid protein would 
hold important potential for presenting multiple epitopes/
antigens or several copies of the same epitope within a single 
Ad vector-based vaccine.
In an effort to create multivalent HIV vaccine vectors, 
our 2008 study explored the use of Ad5 HVR2 and HVR5 
in hopes of creating vectors which contained HIV antigenic 
epitopes at both locales. To compare the flexibility and capac-
ities of Ad5 HVR2 and HVR5, we genetically incorporated 
identical epitopes of incrementally increasing size within 
HVR2 or HVR5 of Ad5 hexon. We incorporated identical 
epitopes ranging from 33 to 83 amino acids within the Ad5 
hexon HVR2 or HVR5 region. Viable viruses were produced 
with incorporations of 33 amino acids plus a 12-amino acid 
linker at HVR2 or HVR5. In addition, viable viruses were 
produced with incorporations of up to 53 amino acids plus a 
12-amino acid linker at HVR5. With respect to identical anti-
gen incorporations at Ad5 HVR2 or HVR5, HVR5 was more 
permissive allowing an epitope incorporation of 65 amino 
acids in total. These model antigens were surface exposed 
via ELISA analysis. In vivo immunization with these vectors 
illustrated an antigen-specific immune response.240
Along these same lines, Abe and colleagues evaluated the 
ability of Ad5-based vectors expressing an HIV transgene to 
induce antigen-specific immune responses under Ad5 preim-
mune conditions. To overcome limitations that are generally 
experienced as a result of PEI to Ad5, they constructed 
vectors that have a modification in the HVR5. Their study 
characterized various immunological parameters generated 
by these vectors such as vector neutralization, acquisition 
of adaptive immune response, and comparison of protec-
tive immunity. First, in order to evaluate the utility of the 
modified Ad vector, they measured the neutralizing activity 
of sera by a modified Ad vector. They administered Ad-Luc 
(luciferase protein expressed as a transgene in the Ad E1 
region), Ad-HisLuc (His6 epitope presented in HVR5 region 
and luciferase protein expressed as a transgene), or Ad-END/
AAALuc vector (containing three amino acid mutations in 
HVR5 and expressing luciferase protein) to mice IM. After 
administration of these vectors, neutralizing activity against 
Ad5 was observed for 0–8 weeks. The hexon-modified vector 
(Ad-HisLuc) generated the lowest Ad5-specific neutralizing 
activity, which was significantly lower than what was gener-
ated by Ad-Luc at weeks 6 and 8, and by Ad-End/AAALuc 
vector at week 8. The individual neutralizing activity of 
Ad-HisLuc immunization was significantly lower than that 
of Ad-Luc immunization. Additional studies performed 
by Abe and colleagues support the concept that modified 
hexon thwarts Ad5 Nabs and promotes cellular immune 
  responses.247 Studies performed by this research group indi-
cate that a change in the immunogenic epitope is necessary 
to avoid neutralization by pre-existing Nabs.
Our recently published work exploits the antigen capsid-
incorporation strategy for HIV vaccination. Our novel vec-
tors were constructed in hopes of moving toward the goal of 
creating vectors that will provide cellular and humoral HIV 
immunity. Our study is the first of its kind to genetically 
incorporate an HIV antigen within the Ad5 hexon HVR2 





Gag transgene (Ad5/HVR2-MPER-L15(Gag)). In this study, 
we successfully incorporated a 24-amino acid epitope of 
HIV-1 within HVR2. The HIV-1 region selected for HVR2 
incorporation was the membrane proximal ectodomain region 
(MPER) derived from HIV-1 glycoprotein 41 (gp41). Our 
rationale for choosing a portion of the MPER (EKNEKEL-
LELDKWASLWNWFDITN) derived from gp41 was based 
on the fact that the gp41 envelope protein ectodomain is a 
target of three broadly neutralizing anti-HIV-1 antibodies.248 
When the MPER was incorporated into HVR2 in combina-
tion with transgene expression, we observed growth kinet-
ics and thermostability changes similar to those of other 
capsid-incorporated vectors generated in other studies,249,250 
indicating that incorporation of the MPER epitope within 
HVR2 was not dramatically detrimental to virological 
characteristics.250,251 In addition, we demonstrated that the 
MPER epitope is surface exposed within HVR2. Most impor-
tantly, we observed a humoral anti-HIV response in mice vac-
cinated with the hexon-modified vector. The MPER-modified 
vector allows boosting compared to AdCMVGag, possibly 
because the Ad5/HVR2-MPER-L15(Gag) Ad elicits less anti-
Ad5 immune response. It is possible that the MPER epitope 
reduced the immunogenicity of the Ad5 vector. This finding 
is noteworthy because HVR2 has not been fully explored 
for antigen capsid-incorporation strategies.252 These vectors 
are currently being analyzed by cryo-electron microscopic 
analysis to determine the critical correlates related to antigen 
placement/configuration and immune response.
In addition, with respect to HIV-1 vaccination, the antigen 
capsid-incorporation strategy has been evaluated within the 
context of HRV . Research groups have constructed human 
rhinovirus:HIV-1 chimeras in an effort to stimulate immunity 
against HIV-1.148,253 In an effort to develop HIV-1 vaccines, 
researchers within this same group generated combinatorial 
libraries of HRV capsid-incorporated HIV-1 gp41 epitope. 
Their results indicated that they were successful in eliciting 
antibodies whose activity can mimic the Nab effect.149
Commercial and clinical Ad development of HIV-1 
vaccines have progressed preferentially more than vector 
systems such as HRV because the flexibility of Ad generally 
exceeds current rhinovirus systems. For example, because 
HRV is a relatively small RNA virus, the HRV platform 
can display an array limited to 60 copies of a single HIV-1 
epitope.148,253 In contrast, the Ad vector platform allows incor-
poration of the HIV-1 MPER epitope into three structurally 
distinct locales, including HVR2, HVR5,247 and protein IX 
(our unpublished data). In comparison, the Ad MPER anti-
gen capsid-incorporation display platform could present an 
array of 720 HIV-1 epitope copies within Ad hexon and 240 
HIV-1 epitope copies within pIX. If a multivalent Ad vector 
is generated with HIV-1 epitopes within the hexon and the 
pIX locales, this would represent 960 HIV epitopes within 
one Ad vector. Another significant difference between the 
Ad and HRV platforms is in the number of locales that have 
been successfully used for heterologous epitope insertion. 
Finally, in contrast to the rhinovirus that lacks this capacity, 
the Ad platform has sufficient coding capacity allowing for 
HIV-1 transgene expression in combination with presenting 
the same or a different antigen on the viral capsid surface. 
This latter finding is important because it provides the basis 
for constructing vectors that will provide cellular and humoral 
HIV-1 immunity. Vectors which provide both cellular and 
humoral immunity may be the way forward with respect to 
prophylactic HIV vaccine development.
Promising results in an effort  
to produce an HIV vaccine
Recently, there have been encouraging developments regard-
ing HIV vaccination. In the 1980s, in Thailand, there was 
a substantial increase in the prevalence of infection with 
HIV-1.254–256 By first observation, these groups consisted of 
intravenous-drug users and commercial sex workers; this 
infected group then expanded to the general population.101 By 
the mid 1990s, the overall seroprevalence of HIV-1 reached a 
peak of 3.7% among members of the Royal Thai Army and 
of 12.5% among people from Northern Thailand.255,257 The 
Thai Ministry of Public Health acted by starting an effective 
HIV-prevention campaign. With this effort, the number of 
new HIV-1 infections per year decreased from an estimated 
143,000 in 1990 to 14,000 in 2007.255,258–260 Although this 
decrease was promising, there was still a desire to do more 
to prevent HIV infection. To achieve this goal, an HIV Phase 
III study was begun.
The Thai Phase III HIV vaccine study, also known as 
RV144, opened in the fall of 2003. The placebo-controlled 
trial tested the safety and effectiveness of a prime-boost 
regimen of two vaccines: ALVAC-HIV vaccine (the prime), 
a modified canarypox vaccine, and AIDSVAX B/E vaccine 
(booster), a gp 120 vaccine. The vaccines were based on the 
subtype E and B HIV-1 strains that commonly circulate in 
Thailand. The subtype B HIV-1 strain is the most commonly 
found strain in the United States. The trial, conducted in the 
Chonburi and Rayong provinces of Thailand, enrolled 16,402 
women and men aged 18–30 years at various levels of risk 
for HIV infection. Study participants received the placebo 
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and 6 months. The placebo or AIDSVAX B/E vaccine was 
given to participants at 3 and 6 months. Participants were 
tested for HIV-1 infection every 6 months for 3 years. During 
each clinic visit, study participants were counseled on how 
to prevent HIV-1 infection.
The results showed that 74 of 8198 placebo recipients 
became infected with HIV-1 compared with 51 of 8197 par-
ticipants who received the vaccine. This level of effectiveness 
in preventing HIV-1 infection was found to be statistically 
significant. The vaccine strategy had no effect, however, on 
the amount of virus in the blood of volunteers who acquired 
HIV-1 infection during the study. Based on the final analysis 
of the study, the surgeon general of the US Army, the trial 
sponsor, announced that the prime-boost investigational 
vaccine regimen was safe and 31% effective in preventing 
HIV-1 infection. With respect to an HIV-1 vaccine that can 
provide sterilizing HIV immunity, this is the best result 
in humans to date. However, the modest protection effect 
appeared limited to low-risk individuals, and there were data 
which suggest that this effect was confined to the first year fol-
lowing administration of the vaccine. Efforts must continue 
to focus on evaluating the immune response induced by the 
vaccine to establish potential correlates of protection.
Conclusion
Over the last three decades, the world has been faced with 
the emergence and subsequent epidemic of HIV/AIDS. 
There has been much progress with respect to diagnosis and 
prevention. On the treatment front, there have been several 
significant advances with respect to drug development (ie, 
ART/HAART). However, there is a desperate need for an 
effective and safe vaccine. There has been tremendous dif-
ficulty with regard to developing a vaccine that provides 
sterilizing immunity. This has been the case due to some of 
the factors mentioned in this review such as HIV diversity, 
immune evasion, and lack of appropriate animal models. Due 
to these obstacles, many researchers assumed that the control 
of HIV-1 viremia by vaccination would be a more realistic 
goal than the development of sterilizing immunity.
The road to a safe and effective HIV-1 vaccine received 
a serious setback in the fall of 2007 with the premature ter-
mination of the Merck-HIV-1 Vaccine STEP trial due to the 
lack of efficacy and early speculation that the vaccine might 
have increased the risk of HIV infection in some popula-
tions of vaccinees. In late 2009, promising results came in 
from Thailand in response to their efforts to create a safe 
and   effective vaccine against HIV-1. A community-based, 
randomized, multicenter, double-blinded, placebo-controlled 
efficacy trial using a prime-boost combination showed 31% 
effectiveness in preventing HIV-1 infection. These results 
lend promise to the hope of producing an HIV-1 vaccine 
vector that yields sterilizing HIV-1 immunity.
In the future, research scientists must work together to 
increase HIV-1 vaccine effectiveness beyond 31%. Realization 
of this goal may be accomplished by some of the techniques 
mentioned in this review, such as acquisition of HIV mucosal 
immunity, development of effective prime-boost strategies, 
development of better animal models, better molecular antigen 
modeling and presentation, avoidance of PEI (by the means of 
using novel vector serotypes in combination with PEGylation), 
and/or induction of Nabs (by means of capsid incorporation of 
HIV antigens within viral vectors). These are just a few consid-
erations that scientists and clinicians must consider with respect 
to the development of an effective and safe HIV-1 vaccine. 
Scientists and clinicians must also consider that one vector or 
scheme may not be sufficient with respect to providing effective 
HIV-1 immunity and some combination of the above-mentioned 
potential strategies may offer the most promising method of 
producing an effective HIV-1 prophylactic vaccine.
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